Table 1.

Glioma patient cohort included in this study*

Patient	Age	Sex	Diagnosis*	WHO Grade	MGMT	IDH
#1	46	f	GBM	IV	unmet	wt
#2	51	f	GBM	IV	n/a	n/a
#3	69	m	GBM	IV	met	wt
#4	60	m	GBM	IV	met	wt
#5	53	m	GBM	IV	met	wt
#6	53	f	GBM	IV	IND	wt
#7	52	m	GBM	IV	unmet	wt
#8	75	m	GBM	IV	IND	wt
#9	65	m	GBM	IV	unmet	wt
#10	65	m	GBM	IV	met	wt
#11	71	m	GBM	IV	IND	wt
#12	81	f	GBM	IV	met	wt
#13	54	m	GBM	IV	unmet	wt
#14	53	f	GBM	IV	met	wt
#15	63	f	GBM	IV	unmet	wt
#16	59	m	Gliosarcoma	IV	unmet	wt
#17	59	m	GBM	IV	unmet	wt
#18	61	m	GBM	IV	unmet	wt
#19	48	f	GBM	IV	met	wt
#20	50	m	GBM	IV	IND	wt
#21	50	m	GBM	IV	unmet	wt
#22	86	m	GBM	IV	met	wt
#23	41	f	GBM	IV	n/a	mut
#24	42	f	AA	III	met	mut
#25	27	f	AA	III	met	mut
#26	48	f	ODG	II	met	mut
#27	25	m	Astrocytoma	II	n/a	mut
#28	49	f	ODG	II	n/a	mut
#29	74	m	Astrocytoma	II	n/a	wt
#30	29	f	ODG	II	met	mut
#31	39	f	Astrocytoma	II	met	mut

*All diagnoses were histopathologically proven after surgical resection or tumor biopsy subsequent to CEST MRI at 7.0 T (AA = anaplastic astrocytoma, GBM = glioblastoma, ODG = oligodendroglioma). n/a = data not available, IND = result of histopathological analysis indeterminate. WHO grade II tumors were considered LGG and WHO grades III‒IV as HGG.